Thrombotic and cardiovascular risks in type two diabetes; Role of platelet hyperactivity

Biomedicine and Pharmacotherapy

Volumn 94, Issue , 2017, Pages 679-686

  Gaiz, Almottesembellah ^a,b   Mosawy, Sapha ^a   Colson, Natalie ^a   Singh, Indu ^a  

^a GRIFFITH UNIVERSITY   (Australia)

^b MUSTANSIRIYAH UNIVERSITY   (Iraq)

Author keywords

CVD; Diabetes; Hyperactive platelets; Oxidative stress; Thrombosis

Indexed keywords

ATHEROSCLEROSIS; BODY MASS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CELL INTERACTION; ENDOTHELIUM CELL; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; OXIDATIVE STRESS; PLATELET HYPERACTIVITY; PRIORITY JOURNAL; REVIEW; THROMBOCYTE; THROMBOCYTE FUNCTION; THROMBOSIS; ANIMAL; COMPLICATION; HYPERGLYCEMIA; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY; RISK FACTOR;

ANIMALS; ATHEROSCLEROSIS; BLOOD PLATELETS; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; HUMANS; HYPERGLYCEMIA; OXIDATIVE STRESS; RISK FACTORS; THROMBOSIS;

EID: 85026744186     PISSN: 07533322     EISSN: 19506007     Source Type: Journal    
DOI: 10.1016/j.biopha.2017.07.121     Document Type: Review

References (76)

1. Deed, G., Ackermann, E., Newman, R., Audehm, R., Arthur, I., Barlow, J., Kennedy, M., Kilov, G., Leow, S., Manski-Nankervis, J.-A., General Practice Management of Type 2 Diabetes. 2014, Royal Australian College of General Practitioners (RACGP), East Melbourne, VIC, Australia.
2. Laakso, M., Hyperglycemia and cardiovascular disease in type 2 diabetes. Diabetes 48:5 (1999), 937–942.
3. Giacco, F., Brownlee, M., Oxidative stress and diabetic complications. Circ. Res. 107:9 (2010), 1058–1070.
4. Stadler, K., Oxidative stress in diabetes. Ahmad, S.I., (eds.) Diabetes: An Old Disease, a New Insight, 2013, Springer New York, New York, NY, 272–287.
5. Kelley, E.E., Paes, A.M.d.A., Yadav, H., Quijano, C., Cassina, A., Trostchansky, A., Interplay between oxidative stress and metabolism in signalling and disease 2016. Oxid. Med. Cell. Longevity, 2017, 2017, 2.
6. Stenberg, P.E., A platelet alpha-granule membrane protein (GMP-140) is expressed on the plasma membrane after activation. J. Cell Biol. 101:3 (1985), 880–886.
7. Shattil, S.J., Hoxie, J.A., Cunningham, M., Brass, L.F., Changes in the platelet membrane glycoprotein IIb.IIIa complex during platelet activation. J. Biol. Chem. 260:20 (1985), 11107–11114.
8. Kestin, A.S., Effect of strenuous exercise on platelet activation state and reactivity. Circulation (New York N.Y.) 88:4 (1993), 1502–1511.
9. Gryglewski, R.J., Mediators produced by the endothelial cell. Hypertension 12:6 (1988), 530–548.
10. Vinik, A.I., Erbas, T., Park, T.S., Nolan, R., Pittenger, G.L., Platelet dysfunction in type 2 diabetes. Diabetes Care 24:8 (2001), 1476–1485.
11. Blache, D., Bourdon, E., Salloignon, P., Lucchi, G., Ducoroy, P., Petit, J.-M., Verges, B., Lagrost, L., Glycated albumin with loss of fatty acid binding capacity contributes to enhanced arachidonate oxygenation and platelet hyperactivity: relevance in patients with type 2 diabetes. Diabetes 64:3 (2015), 960–972.
12. Knebel, S.M., Sprague, R.S., Stephenson, A.H., Prostacyclin receptor expression on platelets of humans with type 2 diabetes is inversely correlated with hemoglobin A1c levels. Prostaglandins Other Lipid Mediators 116–117 (2015), 131–135.
13. DiMinno, G., Silver, M.J., Cerbone, A.M., Riccardi, G., Rivellese, A., Mancini, M., Platelet fibrinogen binding in diabetes mellitus. Differences between binding to platelets from nonretinopathic and retinopathic diabetic patients. Diabetes 35:2 (1986), 182–185.
14. Bensoussan, D., Levy Toledano, S., Passa, P., Caen, J., Caniver, J., Platelet hyperaggregation and increased plasma level of Von Willebrand factor in diabetics with retinopathy. Diabetologia 11:4 (1975), 307–312.
15. Kutti, J., Wadenvik, H., Henestam, B., Stenstrom, G., Evaluation of platelet reactivity in diabetes mellitus. Acta Med. Scand. 219:2 (1986), 195–199.
16. Van Zile, J., Kilpatrick, M., Laimins, M., Sagel, J., Colwell, J., Virella, G., Platelet aggregation and release of ATP after incubation with soluble immune complexes purified from the serum of diabetic patients. Diabetes 30:7 (1981), 575–579.
17. Colwell, J.A., Halushka, P.V., Sarji, K., Levine, J., Sagel, J., Nair, R.M., Altered platelet function in diabetes mellitus. Diabetes 25:2 suppl (1976), 826–831.
18. Sagel, J., Colwell, J.A., Crook, L., Laimins, M., Increased platelet aggregation in early diabetus mellitus. Ann. Intern. Med. 82:6 (1975), 733–738.
19. Inui, Y., Suehiro, T., Kumon, Y., Hashimoto, K., Platelet volume and urinary prostanoid metabolites in non-insulin-dependent diabetes mellitus. J. Atheroscler. Thromb. 1:2 (1994), 108–112.
20. Halushka, P.V., Rogers, R.C., Loadholt, C.B., Colwell, J.A., Increased platelet thromboxane synthesis in diabetes mellitus. J. Lab. Clin. Med. 97:1 (1981), 87–96.
21. Gerrard, J.M., Stuart, M.J., Rao, G.H., Steffes, M.W., Mauer, S.M., Brown, D.M., White, J.G., Alteration in the balance of prostaglandin and thromboxane synthesis in diabetic rats. J. Lab. Clin. Med. 95:6 (1980), 950–958.
22. Vinik, A.I., Erbas, T., Tae Sun, P., Nolan, R., Pinnenger, G.L., Platelet dysfunction in type 2 diabetes. Diabetes Care 24:8 (2001), 1476–1485.
23. Ross, R., Atherosclerosis — an inflammatory disease. New Engl. J. Med. 340:2 (1999), 115–126.
24. Ferroni, P., Basili, S., Falco, A., Davi, G., Platelet activation in type 2 diabetes mellitus. J. Thromb. Haemost. 2:8 (2004), 1282–1291.
25. Aboonabi, A., Singh, I., The effectiveness of antioxidant therapy in aspirin resistance, diabetes population for prevention of thrombosis. Biomed. Pharmacother. 83 (2016), 277–282.
26. Vane, J.R., Anggard, E.E., Botting, R.M., Regulatory functions of the vascular endothelium. N. Engl. J. Med. 323:1 (1990), 27–36.
27. Forstermann, U., Mugge, A., Alheid, U., Haverich, A., Frolich, J.C., Selective attenuation of endothelium-mediated vasodilation in atherosclerotic human coronary arteries. Circ. Res. 62:2 (1988), 185–190.
28. Abe, Y., El-Masri, B., Kimball, K.T., Pownall, H., Reilly, C.F., Osmundsen, K., Smith, C.W., Ballantyne, C.M., Soluble cell adhesion molecules in hypertriglyceridemia and potential significance on monocyte adhesion. Arterioscler. Thromb. Vasc. Biol. 18:5 (1998), 723–731.
29. Rui, W., Guan, L., Zhang, F., Zhang, W., Ding, W., PM2.5-induced oxidative stress increases adhesion molecules expression in human endothelial cells through the ERK/AKT/NF-(B-dependent pathway. J. Appl. Toxicol. 36:1 (2016), 48–59.
30. Santhakumar, A.B., Bulmer, A.C., Singh, I., A review of the mechanisms and effectiveness of dietary polyphenols in reducing oxidative stress and thrombotic risk. J. Hum. Nutr. Diet 27:1 (2014), 1–21.
31. Matteucci, E., Giampietro, O., Oxidative stress in families of type 1 diabetic patients. Diabetes Care 23:8 (2000), 1182–1186.
32. Singh, I., Mok, M., Christensen, A.-M., Turner, A.H., Hawley, J.A., The effects of polyphenols in olive leaves on platelet function. Nutr. Metab. Cardiovasc. Dis. 18:2 (2008), 127–132.
33. Christie, D.J., Kottke-Marchant, K., Gorman, R.T., Hypersensitivity of platelets to adenosine diphosphate in patients with stable cardiovascular disease predicts major adverse events despite antiplatelet therapy. Platelets 19:2 (2008), 104–110.
34. Balasubramaniam, K., Viswanathan, G.N., Marshall, S.M., Zaman, A.G., Increased atherothrombotic burden in patients with diabetes mellitus and acute coronary syndrome: a review of antiplatelet therapy. Cardiol. Res. Pract., 2012, 2012, 909154.
35. Halushka, P., Rogers, R.C., Loadholt, C.B., Colwell, J., Increased platelet thromboxane synthesis in diabetes mellitus. J. Lab. Clin. Med. 97:1 (1981), 87–96.
36. Eibl, N., Krugluger, W., Streit, G., Schrattbauer, K., Hopmeier, P., Schernthaner, G., Improved metabolic control decreases platelet activation markers in patients with type‐2 diabetes. Eur. J. Clin. Invest. 34:3 (2004), 205–209.
37. Colwell, J.A., Nesto, R.W., The Platelet in Diabetes Focus on prevention of ischemic events. Diabetes Care 26:7 (2003), 2181–2188.
38. Li, Y., Woo, V., Bose, R., Platelet hyperactivity and abnormal Ca2+ homeostasis in diabetes mellitus. Am. J. Physiology-Heart Circulatory Physiol. 280:4 (2001), H1480–H1489.
39. Beckman, J.A., Creager, M.A., Libby, P., Diabetes and atherosclerosis: epidemiology, pathophysiology, and management. JAMA 287:19 (2002), 2570–2581.
40. Gawaz, M., Ott, I., Reininger, A., Neumann, F., Effects of magnesium on platelet aggregation and adhesion. Magnesium modulates surface expression of glycoproteins on platelets in vitro and ex vivo. Thromb. Haemost. 72:6 (1994), 912–918.
41. Weyrich, A., Lindemann, S., Zimmerman, G., The evolving role of platelets in inflammation. J. Thromb. Haemost. 1:9 (2003), 1897–1905.
42. Ferreiro, J.L., Angiolillo, D.J., Diabetes and antiplatelet therapy in acute coronary syndrome. Circulation 123:7 (2011), 798–813.
43. Nolan, C.J., Damm, P., Prentki, M., Type 2 diabetes across generations: from pathophysiology to prevention and management. Lancet 378:9786 (2011), 169–181.
44. Shamseddeen, H., Getty, J.Z., Hamdallah, I.N., Ali, M.R., Epidemiology and economic impact of obesity and type 2 diabetes. Surg. Clinics North Am. 91:6 (2011), 1163–1172.
45. M.A. Atkinson, G.S. Eisenbarth, A.W. Michels, Type 1 diabetes The Lancet 383 9911 (2014)69–82.
46. Wisinski, J.A., Kimple, M.E., Platelet dysfunction in type 1 diabetes: stressing the thromboxanes. Diabetes 65:2 (2016), 349–351.
47. de Ferranti, S.D., de Boer, I.H., Fonseca, V., Fox, C.S., Golden, S.H., Lavie, C.J., Magge, S.N., Marx, N., McGuire, D.K., Orchard, T.J., Zinman, B., Eckel, R.H., Type 1 diabetes mellitus and cardiovascular disease. A Sci. Statement Am. Heart Assoc. Am. Diabetes Assoc. 130:13 (2014), 1110–1130.
48. Beckman, J.A., Paneni, F., Cosentino, F., Creager, M.A., Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: part II. Eur. Heart J. 34:31 (2013), 2444–2452.
49. Zaccardi, F., Rizzi, A., Petrucci, G., Ciaffardini, F., Tanese, L., Pagliaccia, F., Cavalca, V., Ciminello, A., Habib, A., Squellerio, I., Rizzo, P., Tremoli, E., Rocca, B., Pitocco, D., Patrono, C., In vivo platelet activation and aspirin responsiveness in type 1 diabetes mellitus. Diabetes, 2015.
50. Seal, C.J., Whole grains and CVD risk. Proc. Nutr. Soc. 65:1 (2006), 24–34.
51. Beaglehole, R., Saracci, R., Panico, S., Cardiovascular diseases: causes, surveillance and prevention. Int. J. Epidemiol. 30:Suppl 1 (2001), S1–4.
52. Waters, A.M., Trinh, L., Chau, T., Bourchier, M., Moon, L., Latest statistics on cardiovascular disease in Australia. Clin. Exp. Pharmacol. Physiol. 40:6 (2013), 347–356.
53. Chiasson, J.-L., Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance the STOP-NIDDM trial. JAMA: J. Am. Med. Assoc., 290(4), 2003, 486.
54. Meigs, J.B., Wilson, P.W., Fox, C.S., Vasan, R.S., Nathan, D.M., Sullivan, L.M., D'agostino, R.B., Body mass index, metabolic syndrome, and risk of type 2 diabetes or cardiovascular disease. J. Clin. Endocrinol. Metab. 91:8 (2006), 2906–2912.
55. Dalton, M., Cameron, A.J., Zimmet, P.Z., Shaw, J.E., Jolley, D., Dunstan, D.W., Welborn, T.A., c. On behalf of the AusDiab steering, Waist circumference, waist–hip ratio and body mass index and their correlation with cardiovascular disease risk factors in Australian adults. J. Intern. Med. 254:6 (2003), 555–563.
56. Bordeaux, B.C., Qayyum, R., Yanek, L.R., Vaidya, D., Becker, L.C., Faraday, N., Becker, D.M., Effect of obesity on platelet reactivity and response to low-dose aspirin. Prev. Cardiol. 13:2 (2010), 56–62.
57. Ziccardi, P., Nappo, F., Giugliano, G., Esposito, K., Marfella, R., Cioffi, M., D'Andrea, F., Molinari, A.M., Giugliano, D., Reduction of inflammatory cytokine concentrations and improvement of endothelial functions in obese women after weight loss over one year. Circulation 105:7 (2002), 804–809.
58. Sibbing, D., von Beckerath, O., Schömig, A., Kastrati, A., von Beckerath, N., Impact of body mass index on platelet aggregation after administration of a high loading dose of 600 mg of clopidogrel before percutaneous Coronary intervention. Am. J. cardiol. 100:2 (2007), 203–205.
59. de Jager, J., Dekker, J.M., Kooy, A., Kostense, P.J., Nijpels, G., Heine, R.J., Bouter, L.M., Stehouwer, C.D.A., Endothelial dysfunction and low-grade inflammation explain much of the excess cardiovascular mortality in individuals with type 2 diabetes The Hoorn Study. Arteriosclerosis Thrombosis Vasc. Biol. 26:5 (2006), 1086–1093.
60. Ferroni, P., Basili, S., Falco, A., Davì, G., Platelet activation in type 2 diabetes mellitus. J. Thromb. Haemost. 2:8 (2004), 1282–1291.
61. E. National Cholesterol Education Program Expert Panel on Detection, A. Treatment of High Blood Cholesterol in, Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report Circulation 106(25)(2002)3143-421.
62. Assmann, G., Schulte, H., Relation of high-density lipoprotein cholesterol and triglycerides to incidence of atherosclerotic coronary artery disease (the PROCAM experience). Prospective Cardiovascular Munster study. Am. J.Cardiol. 70:7 (1992), 733–737.
63. Lewis, G.F., Rader, D.J., New insights into the regulation of HDL metabolism and reverse cholesterol transport. Circ. Res. 96:12 (2005), 1221–1232.
64. Qin, Y., Xia, M., Ma, J., Hao, Y., Liu, J., Mou, H., Cao, L., Ling, W., Anthocyanin supplementation improves serum LDL-and HDL-cholesterol concentrations associated with the inhibition of cholesteryl ester transfer protein in dyslipidemic subjects. Am. J. Clin. Nutr. 90:3 (2009), 485–492.
65. Beaglehole, R., Saracci, R., Panico, S., Cardiovascular diseases: causes, surveillance and prevention. Int. J. Epidemiol., 30(suppl 1), 2001, S1.
66. Almer, L.O., Nilsson, I.M., On fibrinolysis in diabetes mellitus. Acta Med. Scand. 198:1–2 (1975), 101–106.
67. Banga, J.D., Sixma, J.J., Diabetes mellitus, vascular disease and thrombosis. Clin. Haematol. 15:2 (1986), 465–492.
68. Juhan-Vague, I., Roul, C., Alessi, M.C., Ardissone, J.P., Heim, M., Vague, P., Increased plasminogen activator inhibitor activity in non insulin dependent diabetic patients?relationship with plasma insulin. Thromb. Haemost. 61:3 (1989), 370–373.
69. Folsom, A.R., Qamhieh, H.T., Wing, R.R., Jeffery, R.W., Stinson, V.L., Kuller, L.H., Wu, K.K., Impact of weight loss on plasminogen activator inhibitor (PAI-1), factor VII, and other hemostatic factors in moderately overweight adults. Arteriosclerosis and Thrombosis: A J. Vasc. Biol./Am. Heart Assoc. 13:2 (1993), 162–169.
70. Whiting, D.R., Guariguata, L., Weil, C., Shaw, J., IDF Diabetes Atlas: global estimates of the prevalence of diabetes for 2011 and 2030. Diabetes Res. Clin. Pract. 94:3 (2011), 311–321.
71. Shah, A.D., Langenberg, C., Rapsomaniki, E., Denaxas, S., Pujades-Rodriguez, M., Gale, C.P., Deanfield, J., Smeeth, L., Timmis, A., Hemingway, H., Type 2 diabetes and incidence of cardiovascular diseases: a cohort study in 1.9 million people. Lancet Diabetes Endocrinol. 3:2 (2015), 105–113.
72. Gregg, E.W., Li, Y., Wang, J., Rios Burrows, N., Ali, M.K., Rolka, D., Williams, D.E., Geiss, L., Changes in diabetes-related complications in the United States 1990–2010. New Engl. J. Med. 370:16 (2014), 1514–1523.
73. Rochette, L., Zeller, M., Cottin, Y., Vergely, C., Diabetes, oxidative stress and therapeutic strategies. Biochim. Biophys. Acta (BBA) − General Subjects 1840:9 (2014), 2709–2729.
74. Ghoshal, K., Bhattacharyya, M., Overview of platelet physiology: its hemostatic and nonhemostatic role in disease pathogenesis. Sci. World J., 2014, 2014, 16.
75. Colwell, J.A., Winocour, P.D., Halushka, P.V., Do platelets have anything to do with diabetic microvascular disease?. Diabetes 32:Supplement 2 (1983), 14–19.
76. Engerman, R.L., Pathogenesis of diabetic retinopathy. Diabetes 38:10 (1989), 1203–1206.